Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway
Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.PMID:37953521 | DOI:10.2340/sju.v58.5923
Source: Scandinavian Journal of Urology - Category: Urology & Nephrology Authors: Christina Tanem M øller Gunnar Tafjord Augun Blindheim Viktor Berge Sophie Foss å Bettina Kulle Andreassen Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Immunotherapy | Norway Health | PET Scan | Statistics | Study | Urology & Nephrology